Abstract
Incidence of pneumococcal disease has increased worldwide in recent years. Response to pneumococcal vaccine is usually measured using the multiserotype enzyme-linked immunosorbent assay (ELISA) pneumococcal test. However, this approach presents several limitations. Therefore, the introduction of new and more robust analytical approaches able to provide information on the efficacy of the pneumococcal vaccine would be very beneficial for the clinical management of patients. Surface plasmon resonance (SPR) has been shown to offer a valuable understanding of vaccines’ properties over the last years. The aim of this study is to evaluate the reliability of SPR for the anti-pneumococcal capsular polysaccharides (anti-PnPs) IgGs quantification in vaccinated. Fast protein liquid chromatography (FPLC) was used for the isolation of total IgGs from serum samples of vaccinated patients. Binding-SPR assays were performed to study the interaction between anti-PnPs IgGs and PCV13. A robust correlation was found between serum levels of anti-PnPs IgGs, measured by ELISA, and the SPR signal. Moreover, it was possible to correctly classify patients into “non-responder”, “responder” and “high-responder” groups according to their specific SPR PCV13 response profiles. SPR technology provides a valuable tool for reliably characterize the interaction between anti-PnPs IgGs and PCV13 in a very short experimental time.
Highlights
Incidence of pneumococcal disease has increased worldwide in recent years
A broad and flattened peak was obtained for the flow-through fractions, containing albumin and other serum proteins not retained in the column, while a narrow peak, corresponding to IgGs enriched elutions was obtained after the purification
To the best of our knowledge, our study demonstrates for the first time that Surface plasmon resonance (SPR)-based approaches may provide highly reliable and accurate measurements of serum anti-pneumococcal capsular polysaccharides (PnPs) IgGs in a very short experimental time (2 min)
Summary
Incidence of pneumococcal disease has increased worldwide in recent years. Response to pneumococcal vaccine is usually measured using the multiserotype enzyme-linked immunosorbent assay (ELISA) pneumococcal test. Surface plasmon resonance (SPR) is an analytical technique that can provide a deeper characterization of the antibody-antigen interaction, very valuable for a better understanding of a patient’s vaccine response This experimental tool has greatly contributed to the research, development, and production of new vaccines in recent years[12,13]. In a more recent study, Khurana et al demonstrated the impact of repeated vaccinations on antibody-affinity maturation using this analytical approach[17,18] Based on these previous reports, the aim of this pilot study was to evaluate the potential of SPR for the quantification of anti-PnPs IgGs in serum of patients after PCV13 vaccination, with a focus on the feasibility of implementing this experimental approach in routine clinical practice
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
